AXA IM bolsters biotech and healthcare team
AXA Investment Managers (AXA IM) has appointed Peter Hughes as a healthcare equity analyst. He will focus on biotechnology.
Based in London, Hughes will support Linden Thomson, manager of the AXA Framlington Biotech Fund and Dani Saurymper, manager of the AXA Framlington Health Fund.
Hughes joins from Architas, London based AXA’s multi-manager investment company, where he was an investment analyst.
Over five years, the AXA Framlington Biotech fund and the AXA Framlington Health fund have returned 253.47%1 and 127.29%1 respectively.
The healthcare franchise was set in 1987 with the launch of the AXA Framlington Health unit trust.
The team manages £1.3bn (€1.7bn) of assets as at end December 2015 across the AXA Framlington Healthcare, AXA WF Framlington Health and AXA Framlington Biotech funds.